4D Molecular Therapeutics FDMT Shares (Basic)
Shares (Basic) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's shares (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's shares (basic)?
- 4D Molecular Therapeutics (FDMT) reported shares (basic) of 68.1M in Q1 2026.
- How has 4D Molecular Therapeutics's shares (basic) changed year-over-year?
- 4D Molecular Therapeutics's shares (basic) increased by 22.1% year-over-year, from 55.7M to 68.1M.
- What is the long-term trend for 4D Molecular Therapeutics's shares (basic)?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's shares (basic) has grown at a 20.4% compound annual growth rate (CAGR), from 129.3M to 225.7M.
- What does shares (basic) mean?
- The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.